Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis.
Bottom Line: Among the 2555 genes analyzed, we found that promyelocytic leukemia (PML), a tumor suppressor gene, was significantly downregulated in I-GIST at both the protein and mRNA levels (P < 0.01; fold difference ≥2.0).Immunohistochemistry of 254 additional cases from multiple clinical facilities showed that PML-negative cases were significantly frequent in the I-GIST group (P < 0.001).The 5-year recurrence-free survival rate was significantly lower in the PML-negative than in the PML-positive cases (60.1% vs 91.7%; P < 0.001).
Affiliation: Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan; Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.Show MeSH
Related in: MedlinePlus
Mentions: We then examined the prognostic value of PML expression in cases stratified according to the tumor site or NIH consensus criteria (Fig.3). In the S-GIST group, the 5-year RFS rate was 61.2% for PML-negative cases and 94.2% for PML-positive cases (P < 0.001; Fig.3a). In contrast, in the I-GIST and other anatomical tumor site group, the difference between PML-positive and negative cases was not statistically significant (Fig.3b,c). With regard to the NIH consensus criteria, the RFS rate was significantly lower in PML-negative than in PML-positive cases within each risk group (Fig.3d–f).
Affiliation: Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan; Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.